Drug Trial Radar · NCT00857545
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Last checked: Nov 19, 2026Latest source record: Sep 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
171
Actual
Start
Jul 2010
Primary completion
Sep 2015
Sponsor
- Lead sponsor
- Gynecologic Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase II trial studies OPT-821 and vaccine therapy to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer that has decreased or disappeared, but the cancer may still be in the body. Biological therapies, such as OPT-821, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines may help the body build an effective immune response to kill tumor cells. It is not yet known whether OPT-821 is more effective with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.
Conditions
- Stage IA Fallopian Tube Cancer
- Stage IA Ovarian Cancer
- Stage IB Fallopian Tube Cancer
- Stage IB Ovarian Cancer
- Stage IC Fallopian Tube Cancer
- Stage IC Ovarian Cancer
- Stage IIA Fallopian Tube Cancer
- Stage IIA Ovarian Cancer
- Stage IIB Fallopian Tube Cancer
- Stage IIB Ovarian Cancer
- Stage IIC Fallopian Tube Cancer
- Stage IIC Ovarian Cancer
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Primary Peritoneal Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer
Interventions
Laboratory Biomarker AnalysisOther
Correlative studies
Polyvalent Antigen-KLH Conjugate VaccineBiological
Given SC
Saponin-based Immunoadjuvant OBI-821Biological
Given SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Every 3 month until 2 years from start of treatment, then every 6 months for 3 years; then annually if patient remains in remission.
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute
Palo Alto, California
UCSF Medical Center-Mount Zion
San Francisco, California
Beebe Medical Center
Lewes, Delaware
Christiana Care Health System-Christiana Hospital
Newark, Delaware
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
Northside Hospital
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois
Saint Vincent Oncology Center
Indianapolis, Indiana
Greater Baltimore Medical Center
Baltimore, Maryland
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
Union Hospital of Cecil County
Elkton, Maryland
Gynecologic Oncology of West Michigan PLLC
Grand Rapids, Michigan
Washington University School of Medicine
St Louis, Missouri
Women's Cancer Center of Nevada
Las Vegas, Nevada
Center of Hope at Renown Medical Center
Reno, Nevada
The Women's Institute for Gynecologic Cancer and Special Pelvic Surgery
Phillipsburg, New Jersey
University of New Mexico Cancer Center
Albuquerque, New Mexico
Southwest Gynecologic Oncology Associates Inc
Albuquerque, New Mexico
University of New Mexico Cancer Center
Albuquerque, New Mexico
Winthrop University Hospital
Mineola, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
Winston-Salem, North Carolina
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio
University of Cincinnati
Cincinnati, Ohio
Case Western Reserve University
Cleveland, Ohio
Miami Valley Hospital
Dayton, Ohio
Kettering Medical Center
Kettering, Ohio
Lake University Ireland Cancer Center
Mentor, Ohio
University of Toledo
Toledo, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Abington Memorial Hospital
Abington, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Women and Infants Hospital
Providence, Rhode Island
AnMed Health Cancer Center
Anderson, South Carolina
Saint Francis Hospital
Greenville, South Carolina
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.